Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression (vol 104, pg 1202, 2019)-MedSci.cn

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression (vol 104, pg 1202, 2019)

Seymour, JF; Marcus, R; Davies, A; Gallop-Evans, E; Grigg, A; Haynes, A; Herold, M; Illmer, T; Nilsson-Ehle, H; Sokler, M; Dunzinger, U; Nielsen, T; Launonen, A; Hiddemann, W

Seymour, JF (corresponding author), Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.; Seymour, JF (corresponding author), Univ Melbourne, Melbourne, Vic, Australia.

HAEMATOLOGICA, 2020; 105 (5): 1465

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression (vol 104, pg 1202, 2019)

科室

工具

服务